A23V2400/157

Novel lactic acid bacteria and use thereof

The present invention discloses novel lactic acid bacteria, which are isolated Lactococcus lactis subsp. lactis LL358 and isolated Lactobacillus salivarius LS159 respectively. By administering the novel lactic acid bacteria of the present invention, renal injury, metabolic syndrome, hyperuricemia, hypocalcemia, and other disorders can be effectively ameliorated or treated.

Novel lactic acid bacteria and use thereof

The present invention discloses novel lactic acid bacteria, which are isolated Lactococcus lactis subsp. lactis LL358 and isolated Lactobacillus salivarius LS159 respectively. By administering the novel lactic acid bacteria of the present invention, renal injury, metabolic syndrome, hyperuricemia, hypocalcemia, and other disorders can be effectively ameliorated or treated.

Fermented infant formula with non digestible oligosaccharides

The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.

Fermented infant formula with non digestible oligosaccharides

The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.

Modified microorganisms expressing saga and related compositions for immunomodulation against infection and cancer immunotherapy

Provided are compositions and methods based in part on the discovery that Enterococcus faecium secreted antigen A (SagA)-expressing bacteria are protective against enteric infections and enhances immune checkpoint inhibitor efficacy against cancer. Bacteria that express SagA or heterologous SagA, or orthologs thereof, are provided, and are included as nutraceutical, pharmaceutical, and probiotic formulations, as well as components of food products, including dairy products.

METHOD FOR FEEDING BLACK SOLDIER FLY LARVAE WITH SELENIUM-RICH BACTERIA SOLUTION

The present invention discloses a method for feeding black soldier fly larvae with a selenium-rich bacteria solution, as follows: inoculating an intestinal bacteria seed liquid of black soldier fly to a fermentation medium at an inoculum size of 1%-3%, and cultivating at 30 C.-37 C. till the log phase to obtain a fermentation broth of log phase; adding sodium selenite to the fermentation broth of log phase to enable the fermentation broth to have a sodium selenite concentration of 10-600 g/mL, then cultivating the fermentation broth at 30 C.-37 C. for 24-36 h to obtain a selenium-rich bacteria solution; and selecting 4-to-6-day-old black soldier fly larvae to be fed, adding the selenium-rich bacteria solution to a feed to enable the feed to have a selenium content of 5-500 mg/kg (wet weight), feeding the black soldier fly larvae with the feed till the end of the fifth instar of the larvae.

MODIFIED MICROORGANISMS EXPRESSING SagA AND RELATED COMPOSITIONS FOR IMMUNOMODULATION AGAINST INFECTION AND CANCER IMMUNOTHERAPY
20250268961 · 2025-08-28 ·

Provided are compositions and methods based in part on the discovery that Enterococcus faecium secreted antigen A (SagA)-expressing bacteria are protective against enteric infections and enhances immune checkpoint inhibitor efficacy against cancer. Bacteria that express SagA or heterologous SagA, or orthologs thereof, are provided, and are included as nutraceutical, pharmaceutical, and probiotic formulations, as well as components of food products, including dairy products.

LACTOBACILLUS PLANTARUM, LACTIC ACID BACTERIA COMPOSITION AND USE THEREOF FOR TREATING AND/OR PREVENTING HEAVY METAL RELATED DISEASES
20250352591 · 2025-11-20 ·

The invention provides a Lactobacillus plantarum NBM-01-07-003, which is scientifically named: Lactobacillus plantarum subsp. plantarum NBM-01-07-003, depositary authority: China General Microbiological Culture Collection Center (CGMCC) of the China Committee for Culture Collection of Microorganisms (CCCCM); address: Institute of Microbiology, Chinese Academy of Sciences, NO.1 Beichen West Road, Chaoyang District, Beijing 100101, China; depositary date: Sep. 4, 2018; depositary number: CGMCC No. 16417. The Lactobacillus plantarum NBM-01-07-003 has a use of adsorbing metals, and is capable of achieving an efficacy of treating and/or preventing metal poisoning or related complications.